Vancomycin PO

C. diff Risk


Oral Bioavailability


Approximate Cost

Spectrum Of Activity


General Information

Common Usage

Only indication is in the treatment of C. difficile infection.

Drug Monitoring

Possibility of accumulation in severe renal dysfunction.

Oral/rectal therapy: serum sample monitoring not typically required. Some systemic absorption of enteral vancomycin may occur in patients with renal failure who have mucosal disruption from colitis. Monitoring serum vancomycin levels may be considered for these patients with renal failure who have severe colitis and require a prolonged course of enteral vancomycin.

Major Interactions

Bile acid sequestrants may diminish the therapeutic effects of vancomycin. Avoid concurrent administration when possible. If use of both agents is necessary, separate doses by at least 2 hours to minimize significant interaction.

Additional Information

No systemic absorption.

May increase vancomycin resistant Enterococci colonization in the gut.


Antimicrobial class: Glycopeptide

Pregnancy category: B

Average serum half life: 0 hours

Biliary penetration: None

CSF penetration: None

Lung penetration: None

Urine penetration: None